imatinib in the adjuvant setting is based on its demonstrated efficacy and tolerability in patients with unresectable and/or metastatic GIST, and its potential benefit in an earlier and minimal residual status, particularly in patients at higher risk of relapse.
American College of Surgeons Oncology Group Trials
The American College of Surgeons Oncology Group (ACOSOG) evaluated the relative benefits of adjuvant imatinib therapy in patients who have undergone complete gross resection of primary GIST in two clinical trials.
American College of Surgeons Oncology Group Z9000
This was a single-arm, open-label, multicenter, phase II study. 35 Patients recruited to the study had primary KIT-positive primary GIST, with a high risk for recurrence (tumor size ≥10cm, tumor rupture, or fewer than five peritoneal metastases). They were required to undergo complete gross resection of the primary GIST. Imatinib 400mg/day was given orally for one year, beginning within 84 days of resection. The patients planned follow-up is for up to 10 years. The trial is closed to accrual and preliminary data have been presented in abstract form, based on 107 evaluable patients. These early data suggest that imatinib was welltolerated by all patients. The study indicated that imatinib can prolong recurrence-free survival (RFS) and is associated with improved OS compared with historical controls (see Table 1 ).
When imatinib treatment was discontinued, patients with exon 9 mutations quickly relapsed (0% RFS at two years), while those with exon 11 mutations experienced a lower rate of recurrence (62% RFS at three years). 35 This indicates a link between the type of tumor mutation and the rate of recurrence. In the metastatic setting, it has been shown that a high dose of imatinib 800mg/day can lead to a significantly superior PFS rate in GIST patients with exon 9 mutations compared with a lower imatinib dose of 400mg/day. 36 Thus, an interesting question for future clinical trials would be to evaluate whether a higher imatinib dose or a longer treatment duration in the adjuvant therapy of GIST patients with a mutation in exon 9 may prove to be more efficacious. Some light may be shed on this matter when the mutational status of the patients on Z9000 and Z9001 are published and compared with the recurrence data.
American College of Surgeons Oncology Group Z9001
This is a recently completed randomized, double-blind, placebocontrolled, cross-over, multicenter phase III study. analysis that showed that a statistical difference had been achieved for the primary study end-point of RFS, favoring the treatment arm.
The preliminary results of this trial have been published based on 713
patients. In the imatinib arm, one-year RFS was 98% compared with 83% in the placebo arm, with a statistically proven absolute benefit of 16%. The early results of this trial indicated that imatinib can improve RFS following complete gross resection of the GIST. No difference in OS between the two treatment arms was observed. However, the study was underpowered to demonstrate this difference and the cross-over design allowed those patients on placebo to receive imatinib on recurrence. Imatinib therapy was well-tolerated in most patients. This phase III trial also indicated that the higher-risk patients benefited the most (see Table 2 ).
Implications of the American College of Surgeons Oncology Group Trials
Based on the preliminary data from the ACOSOG trials, the National The optimal duration of adjuvant imatinib treatment is currently being investigated by an ongoing multicenter phase III Scandinavian Sarcoma Group (SSG/AIO) XVIII trial. 40 Patients with high-/very-highrisk primary GIST stratified by size and mitotic rate who have undergone complete gross resection of the tumor will be randomized to receive either a short (12 months) or a long (36 months) duration of adjuvant imatinib 400mg/day. The estimated accrual for the study is 400 patients. The patients will be followed up for five years.
The primary outcome measure is RFS, while OS is a secondary outcome measure.
Overall Survival with Adjuvant Imatinib Treatment
An important treatment outcome of adjuvant therapy in oncology is to improve OS. Early data from the AZ9000 study have shown an either imatinib 400mg/day or placebo once daily for two years. After completion of the treatment, the patient follow-up will be every three months for two years. At that point, patients will be followed every four months for three years and at least annually thereafter.
In this study, the primary outcome measure is OS, while secondary outcome measures include RFS and relapse-free interval. The treatment phase of the trial was recently completed and the results are highly anticipated.
Summary
GIST, a life-threatening disease, is expected to affect at least 5,000
people each year in the US. While surgery is the standard of care for primary GISTs, most of these patients will recur within two years of surgery and there is a need for adjuvant therapy in high-risk patients 
